The Remedor Biomed technology platform is based on the combination of two naturally-occurring glycoproteints: erythropoietin (EPO) and fibronectin (FN).
The combined topical administration of these two proteins has been shown to have a synergistic effect that promotes wound healing and connective tissue reconstruction.
Due to the successful preclinical studies, the company is currently preparing for Phase I clinical studies.